PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26316187-0 2015 Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors. Moclobemide 33-44 monoamine oxidase A Homo sapiens 0-19 26316187-5 2015 RESULTS: Mean brain MAO-A occupancies were 74.23+-8.32% for moclobemide at 300-600 mg daily (n = 11), 83.75+-5.52% for moclobemide at 900-1200 mg daily (n = 9), and 86.82+-6.89% for phenelzine at 45-60 mg daily (n = 4). Moclobemide 60-71 monoamine oxidase A Homo sapiens 20-25 26316187-8 2015 CONCLUSIONS: These findings suggest that for first-line MDE treatment, daily moclobemide doses of 300-600mg correspond to a MAO-A occupancy of 74%, whereas for treatment-resistant MDE, either phenelzine or higher doses of moclobemide correspond to a MAO-A occupancy of at least 84%. Moclobemide 77-88 monoamine oxidase A Homo sapiens 124-129 26316187-8 2015 CONCLUSIONS: These findings suggest that for first-line MDE treatment, daily moclobemide doses of 300-600mg correspond to a MAO-A occupancy of 74%, whereas for treatment-resistant MDE, either phenelzine or higher doses of moclobemide correspond to a MAO-A occupancy of at least 84%. Moclobemide 77-88 monoamine oxidase A Homo sapiens 250-255 26316187-10 2015 The findings provide a rationale in treatment algorithm design to raise moclobemide doses to inhibit more MAO-A sites, but suggest switching from high-dose moclobemide to phenelzine is best justified by binding to additional targets. Moclobemide 72-83 monoamine oxidase A Homo sapiens 106-111 23361656-3 2013 MAO activities of the compounds were compared with moclobemide and selegiline and all the compounds were found to inhibit human MAO-A selectively. Moclobemide 51-62 monoamine oxidase A Homo sapiens 128-133 25466703-3 2015 METHODS: In this study, we investigated the effects of both nicotine (6-mg gum) and pharmacologically induced MAO-A inhibition via moclobemide (75 mg) on P50 event-related potential-indexed sensory gating in a sample of 24 healthy non-smoking males. Moclobemide 131-142 monoamine oxidase A Homo sapiens 110-115 24115740-7 2014 Under identical experimental conditions, other established inhibitors of MAO-A and antidepressants provided the following IC50 values: clorgyline 16 nM, harmaline 20 nM, toloxatone 6.7 muM and moclobemide >500 muM. Moclobemide 193-204 monoamine oxidase A Homo sapiens 73-78 23153282-2 2012 All the synthesized compounds showed in vitro high affinity and selectivity toward MAO-A isoenzyme, compared to clorgyline and moclobemide, with Ki values on the picomolar range. Moclobemide 127-138 monoamine oxidase A Homo sapiens 83-88 23437843-3 2013 6"-Sulfonyloxy derivatives exhibited outstanding affinities to MAO-A (7.0 nM < IC50 < 49 nM, much higher than moclobemide) and a pronounced MAO-A/B selectivity. Moclobemide 116-127 monoamine oxidase A Homo sapiens 63-68 22396688-2 2012 The present study aimed to compare the treatment adherence of SAD patients who were taking either SSRIs or reversible inhibitors of MAO-A (moclobemide) by measuring treatment duration and all-cause discontinuation rates of pharmacotherapy in a natural clinical setting. Moclobemide 139-150 monoamine oxidase A Homo sapiens 132-137 21570786-2 2012 We report four cases of fatal serotonin toxicity caused by the combination of MDMA and moclobemide, a reversible MAO-A inhibitor with potent serotonergic activity. Moclobemide 87-98 monoamine oxidase A Homo sapiens 113-118 15804499-5 2005 In humans, co-administration of MDMA with the reversible MAO-A inhibitor moclobemide has led to increased apparent toxicity with ensuing fatalities. Moclobemide 73-84 monoamine oxidase A Homo sapiens 57-62 21463543-0 2011 Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John"s wort: an [11C]-harmine PET study. Moclobemide 91-102 monoamine oxidase A Homo sapiens 0-19 21463543-8 2011 Monoamine oxidase A VT decreased significantly throughout all regions after moclobemide treatment in patients with MDD compared with controls (repeated-measures analysis of variance, F1,15 = 71.08-130.06, p < 0.001 for all regions, mean occupancy 74% [standard deviation 6%]). Moclobemide 76-87 monoamine oxidase A Homo sapiens 0-19 21463543-13 2011 The magnitude of MAO-A blockade during moclobemide treatment exceeds the elevation of MAO-A binding during illness by at least 30%, suggesting that the treatment effect should exceed the disease effect when designing selective antidepressants for this target. Moclobemide 39-50 monoamine oxidase A Homo sapiens 17-22 19687003-3 2009 Moclobemide is a reversible inhibitor of monoamine oxidase (MAO)-A, selegiline is an irreversible selective inhibitor of MAO-B, and paroxetine is a selective serotonin reuptake inhibitor. Moclobemide 0-11 monoamine oxidase A Homo sapiens 41-66 16702990-2 2006 Moclobemide (MB) is an antidepressant drug that selectively and reversibly inhibits monoamine oxidase-A. Moclobemide 0-11 monoamine oxidase A Homo sapiens 84-103 16702990-2 2006 Moclobemide (MB) is an antidepressant drug that selectively and reversibly inhibits monoamine oxidase-A. Moclobemide 13-15 monoamine oxidase A Homo sapiens 84-103 16079787-8 2006 Moclobemide treatment leads to a 64% to 79% MAO-A blockade across brain regions, a result that supports the specificity of [(11)C]-harmine binding to MAO-A. Moclobemide 0-11 monoamine oxidase A Homo sapiens 44-49 16079787-8 2006 Moclobemide treatment leads to a 64% to 79% MAO-A blockade across brain regions, a result that supports the specificity of [(11)C]-harmine binding to MAO-A. Moclobemide 0-11 monoamine oxidase A Homo sapiens 150-155 20711287-1 2005 BACKGROUND: Moclobemide, a benzamide, is one of the new-generation monoamine oxidase-A inhibitors (MAO-AIs) which belongs to the class of reversible inhibitors of monoamine oxidase (RIMA). Moclobemide 12-23 monoamine oxidase A Homo sapiens 67-86 12131599-3 2002 A randomized placebo-controlled, double-blind multi-site trial of moclobemide, a reversible inhibitor of monoamine oxidase A, was undertaken with 390 subjects. Moclobemide 66-77 monoamine oxidase A Homo sapiens 105-124 15048616-1 2004 BACKGROUND: Moclobemide, a reversible and selective inhibitor of the MAO-A isoenzyme, is marketed as an antidepressant that lacks autonomic and cognitive side effects. Moclobemide 12-23 monoamine oxidase A Homo sapiens 69-74 12833310-0 2003 Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide. Moclobemide 96-107 monoamine oxidase A Homo sapiens 80-85 12606609-9 2003 ), a selective MAOI-B but is completely blocked by a pretreatment with moclobemide (MAOI-A; 10 mg/kg). Moclobemide 71-82 monoamine oxidase A Homo sapiens 84-90 15907150-5 2005 Second-line treatments include MAOIs (e.g. phenelzine) and reversible inhibitors of monoamine oxidase A (e.g. moclobemide), while some benzodiazepines and antiepileptics (e.g. clonazepam and pregabalin) may also be useful. Moclobemide 110-121 monoamine oxidase A Homo sapiens 84-103 22033639-8 2003 Three double-blind, placebo-controlled trials have been conducted showing promising results for the selective serotonin reuptake inhibitors (SSRIs) sertraline and fluoxetine, as well as for moclobemide, a reversible inhibitor of monoamine oxidase A. Moclobemide 190-201 monoamine oxidase A Homo sapiens 229-248 12765230-1 2003 The antidepressant moclobemide (Aurorix) is a reversible inhibitor of monoamine oxidase-A. Moclobemide 19-30 monoamine oxidase A Homo sapiens 70-89 12765230-1 2003 The antidepressant moclobemide (Aurorix) is a reversible inhibitor of monoamine oxidase-A. Moclobemide 32-39 monoamine oxidase A Homo sapiens 70-89 12765230-6 2003 Although dietary restrictions during moclobemide therapy are not considered necessary, the combination of large quantities of moclobemide and tyramine-containing products seems to be lethal, probably because monoamine oxidase-A selectivity is overwhelmed after massive overdoses. Moclobemide 126-137 monoamine oxidase A Homo sapiens 208-227 12665046-1 2002 This randomized, prospective, double-blind study evaluated the efficacy and tolerability of moclobemide, a reversible, selective inhibitor of monoamine oxidase-A, in reducing the frequency and severity of hot flashes. Moclobemide 92-103 monoamine oxidase A Homo sapiens 142-161 12163988-0 2002 Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter. Moclobemide 0-11 monoamine oxidase A Homo sapiens 100-119 11309556-1 2001 BACKGROUND: Moclobemide, an antidepressant with selective monoamine oxidase-A inhibitory action, is known to be metabolized by CYP2C19 and is also reported to be an inhibitor of CYP2C19, CYP2D6, and CYP1A2. Moclobemide 12-23 monoamine oxidase A Homo sapiens 58-77 11999916-1 2002 Moclobemide is a specific and reversible monoamine oxidase-A (MAO-A) inhibitor. Moclobemide 0-11 monoamine oxidase A Homo sapiens 41-60 11999916-1 2002 Moclobemide is a specific and reversible monoamine oxidase-A (MAO-A) inhibitor. Moclobemide 0-11 monoamine oxidase A Homo sapiens 62-67 11801236-5 2002 Among the reversible inhibitors of monoamine oxidase A, brofaromine may also be an effective drug, while moclobemide appears to be less potent. Moclobemide 105-116 monoamine oxidase A Homo sapiens 35-54 11422001-1 2001 AIMS: To assess the effect of a reversible MAO-A inhibitor, moclobemide, on the single-dose pharmacokinetics of almotriptan and assess the clinical consequences of any interaction. Moclobemide 60-71 monoamine oxidase A Homo sapiens 43-48 12190330-12 2002 Coadministration with a MAO-A inhibitor, moclobemide, leads to a significant increase in sumatriptan plasma concentrations and is contraindicated. Moclobemide 41-52 monoamine oxidase A Homo sapiens 24-29 11465638-1 2001 RATIONALE AND OBJECTIVES: We tested the hypothesis that the selective reversible MAO-A inhibitor moclobemide has a specific therapeutic effect on erectile dysfunction independent of its antidepressive properties. Moclobemide 97-108 monoamine oxidase A Homo sapiens 81-86 11030484-3 2000 METHOD: Ninety patients with chronic fatigue syndrome, diagnosed with our system that approximates CDC criteria, participated in a randomized, placebo-controlled, double-blind trial of 450 to 600 mg/day of moclobemide, a novel reversible inhibitor of monoamine oxidase-A. Moclobemide 206-217 monoamine oxidase A Homo sapiens 251-270 11195257-1 2001 A 6-week double-blind placebo-controlled trial was carried out to examine the efficacy and tolerability of moclobemide, a monoamine oxidase type A selective and reversible inhibitor, in the treatment of bulimia nervosa. Moclobemide 107-118 monoamine oxidase A Homo sapiens 122-146 11460889-9 2001 Inhibition of triptan metabolism by monoamine oxidase A inhibitors, e.g. moclobemide, may raise circulating triptan concentrations, although this does not yet seem to have led to reported clinical problems. Moclobemide 73-84 monoamine oxidase A Homo sapiens 36-55 10417495-3 1999 Antidepressants such as the MAO-A inhibitor moclobemide may be used in patients with chronic headache syndromes. Moclobemide 44-55 monoamine oxidase A Homo sapiens 28-33 10760560-3 2000 Little is known on the immune effects of moclobemide, a reversible monoamine oxidase A inhibitor. Moclobemide 41-52 monoamine oxidase A Homo sapiens 67-86 11249525-7 2000 There is also an absolute contraindication for the concurrent administration of the MAO-A inhibitor moclobemide and rizatriptan. Moclobemide 100-111 monoamine oxidase A Homo sapiens 84-89 10417495-14 1999 CONCLUSIONS: Moclobemide inhibited the metabolism of rizatriptan and its active N-monodesmethyl metabolite through inhibition of MAO-A. Moclobemide 13-24 monoamine oxidase A Homo sapiens 129-134 10063483-0 1999 Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Moclobemide 71-82 monoamine oxidase A Homo sapiens 46-70 10334000-2 1999 Effects of 150-400 mg/day of moclobemide, a reversible monoamine oxidase A inhibitor, were studied in a 3-month open design in 10 MS patient with DSM-IV-diagnosed depression. Moclobemide 29-40 monoamine oxidase A Homo sapiens 55-74 10333164-0 1999 Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor--results of the drug utilization observation studies. Moclobemide 69-80 monoamine oxidase A Homo sapiens 95-100 9663810-24 1998 The effects of the two drugs on platelet MAO activity and plasma DHPG concentration are in agreement with previous reports and consistent with the relative selectivity of moclobemide for MAO-A and of selegiline for MAO-B. Moclobemide 171-182 monoamine oxidase A Homo sapiens 187-192 10410765-1 1999 Moclobemide, the first reversible inhibitor of MAOA (so-called RIMA) to become widely available for clinical use, is an effective and well-tolerated antidepressant. Moclobemide 0-11 monoamine oxidase A Homo sapiens 47-51 9663810-22 1998 CONCLUSIONS: The potentiation of tyramine-evoked mydriasis by moclobemide is likely to reflect the inhibition of MAO-A activity in the iris, consistent with the activity of this enzyme in sympathetic nerve terminals. Moclobemide 62-73 monoamine oxidase A Homo sapiens 113-118 9987207-1 1999 OBJECTIVE: To determine the efficacy of substituting moclobemide, a reversible monoamine oxidase-A inhibitor, for fluoxetine to reverse fluoxetine-induced sexual dysfunction in patients with depression. Moclobemide 53-64 monoamine oxidase A Homo sapiens 79-98 9704873-1 1998 The onset of action (during the first 2 weeks of treatment) of moclobemide (450 mg/day), a reversible MAO-A inhibitor, was compared in a double-blind, multi-center trial with clomipramine (150 mg/day) on dimensional and global depressive symptoms in 124 hospitalized patients suffering from a major depressive episode according to DSM-III-R criteria and with blunted affect and retardation. Moclobemide 63-74 monoamine oxidase A Homo sapiens 102-107 9656095-2 1998 First, two social phobia studies which used the monoamine oxidase type A inhibitors brofaromine and moclobemide are considered. Moclobemide 100-111 monoamine oxidase A Homo sapiens 48-72 9579294-0 1998 The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson"s disease. Moclobemide 26-37 monoamine oxidase A Homo sapiens 62-81 9579294-1 1998 In this open study, the therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, was tested in 20 patients with Parkinson"s disease who developed levodopa-induced motor response complications. Moclobemide 46-57 monoamine oxidase A Homo sapiens 82-101 9534836-1 1998 BACKGROUND: Moclobemide, a reversible inhibitor of monoamine oxidase A, previously has been reported to have efficacy in the treatment of social phobia. Moclobemide 12-23 monoamine oxidase A Homo sapiens 51-70 9466172-1 1997 Moclobemide is a reversible selective inhibitor of monoamine oxidase A. Moclobemide 0-11 monoamine oxidase A Homo sapiens 51-70 9399014-5 1997 Moclobemide, a monoamine oxidase A (MAO-A) inhibitor, decreased the clearance of zolmitriptan and, in particular, 183C91. Moclobemide 0-11 monoamine oxidase A Homo sapiens 15-34 9399014-5 1997 Moclobemide, a monoamine oxidase A (MAO-A) inhibitor, decreased the clearance of zolmitriptan and, in particular, 183C91. Moclobemide 0-11 monoamine oxidase A Homo sapiens 36-41 18591080-1 1997 Moclobemide, a potent reversible monoamine-oxidase A (MAO-A) inhibitor, is an effective antidepressant that does not cause impairment of cognitive function in elderly patients and might be beneficial to motor deficits in Parkinson"s disease (PD). Moclobemide 0-11 monoamine oxidase A Homo sapiens 33-52 18591080-1 1997 Moclobemide, a potent reversible monoamine-oxidase A (MAO-A) inhibitor, is an effective antidepressant that does not cause impairment of cognitive function in elderly patients and might be beneficial to motor deficits in Parkinson"s disease (PD). Moclobemide 0-11 monoamine oxidase A Homo sapiens 54-59 7593725-2 1995 For the purpose of this analysis of the antidepressant efficacy of the reversible inhibitor of monoamine oxidase A moclobemide, all hospitalized cases were selected from the current database of comparative studies and compared with the standard tricyclics imipramine and clomipramine. Moclobemide 115-126 monoamine oxidase A Homo sapiens 95-114 9273760-2 1997 Moclobemide is a reversible inhibitor of the monoamine oxidase type A (RIMA). Moclobemide 0-11 monoamine oxidase A Homo sapiens 45-69 9272198-0 1997 Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression. Moclobemide 139-150 monoamine oxidase A Homo sapiens 92-111 9347378-2 1997 An international, multicenter, placebo-controlled study was undertaken to determine the safety and antidepressant efficacy of moclobemide, a new reversible inhibitor of monoamine oxidase A, and imipramine in the treatment of dysthymia (DSM-III-R). Moclobemide 126-137 monoamine oxidase A Homo sapiens 169-188 9347385-2 1997 Moclobemide, which is a reversible inhibitor of monoamine oxidase-A, is relatively free of these limitations and is therefore potentially useful in the treatment of post-traumatic stress disorder. Moclobemide 0-11 monoamine oxidase A Homo sapiens 48-67 9074307-2 1997 This review examines the evidence in support of classical monoamine oxidase inhibitor (MAOI) agents and the selective reversible monoamine oxidase type A inhibitor moclobemide in continuation and maintenance therapy. Moclobemide 164-175 monoamine oxidase A Homo sapiens 129-153 9174681-0 1997 MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography. Moclobemide 54-65 monoamine oxidase A Homo sapiens 0-5 8961085-0 1996 Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide. Moclobemide 104-115 monoamine oxidase A Homo sapiens 74-93 8961085-2 1996 This study investigated the safety and tolerability of concomitant administration to 12 healthy subjects of both genders (aged 19-36 years) of ephedrine and moclobemide, a reversible MAO-A inhibitor. Moclobemide 157-168 monoamine oxidase A Homo sapiens 183-188 8875133-2 1996 Unlike older monoamine oxidase inhibitors, which irreversibly and nonselectively bind monoamine oxidase (MAO), moclobemide is a reversible and selective inhibitor of the MAO-A isozyme. Moclobemide 111-122 monoamine oxidase A Homo sapiens 170-175 8923113-4 1996 A reversible inhibitor of monoamine oxidase A, moclobemide, is better tolerated and safer than the irreversible monoamine oxidase inhibitors and placebo-controlled studies have also demonstrated efficacy for this compound; moreover, positive results from a small study of brofaromine also support the efficacy of this class of compounds. Moclobemide 47-58 monoamine oxidase A Homo sapiens 26-45 8923114-3 1996 Moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA) which has an established place in the treatment of depression. Moclobemide 0-11 monoamine oxidase A Homo sapiens 41-60 9005342-2 1996 With the introduction of moclobemide as the first reversible and selective inhibitor of monoamine oxidase (type A), the therapeutic principle of monoamine oxidase inhibition gained new importance. Moclobemide 25-36 monoamine oxidase A Homo sapiens 88-113 8713690-8 1996 Recently, agents that are not only selective, but reversible in their inhibition of MAO-A (RIMAs) have been synthesised (e.g. moclobemide and toloxatone), and have proven antidepressant efficacy. Moclobemide 126-137 monoamine oxidase A Homo sapiens 84-89 9033760-1 1996 We report a case of severe serotonin syndrome after self-poisoning with two antidepressant drugs, paroxetine (a selective inhibitor of serotonin reuptake) and moclobemide (a reversible inhibitor of MAO-A). Moclobemide 159-170 monoamine oxidase A Homo sapiens 198-203 8582117-0 1995 Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Moclobemide 63-74 monoamine oxidase A Homo sapiens 33-52 8582117-4 1995 Moclobemide is an example of a reversible MAO-A inhibitor which has been extensively studied and whose pharmacokinetic, clinical pharmacological and toxicological profiles have been thoroughly defined. Moclobemide 0-11 monoamine oxidase A Homo sapiens 42-47 8557884-2 1995 The results demonstrated that in agitated-anxious depressive patients (defined by HAMD factor score or HAMD item 9) a nonsedative, reversible MAO-A inhibitor moclobemide has about equal efficacy as imipramine or sedative antidepressants. Moclobemide 158-169 monoamine oxidase A Homo sapiens 142-147 7586937-0 1995 A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Moclobemide 44-55 monoamine oxidase A Homo sapiens 13-32 9304853-2 1997 Moclobemide is a selective and reversible inhibitor of monoamine oxidase type A. Moclobemide 0-11 monoamine oxidase A Homo sapiens 55-79 9259175-14 1997 Moclobemide is a selective inhibitor of monoamine oxidase type A. Moclobemide 0-11 monoamine oxidase A Homo sapiens 40-64 9324719-3 1997 The selective and reversible monoamine oxidase inhibitor type A (MAO-A inhibitor), moclobemide (Aurorix), is much better tolerated and safer to use. Moclobemide 83-94 monoamine oxidase A Homo sapiens 65-70 9324719-3 1997 The selective and reversible monoamine oxidase inhibitor type A (MAO-A inhibitor), moclobemide (Aurorix), is much better tolerated and safer to use. Moclobemide 96-103 monoamine oxidase A Homo sapiens 65-70 9038453-1 1996 We report a case of low thoracic epidural and general anaesthesia in a patient receiving moclobemide, a new selective inhibitor of monoamine oxidase A. Moclobemide 89-100 monoamine oxidase A Homo sapiens 131-150 8923574-0 1996 Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. Moclobemide 42-53 monoamine oxidase A Homo sapiens 8-27 8923574-3 1996 In order to evaluate the predictive ability of monoamine oxidase-A inhibition for therapeutic efficacy, the start of treatment effects of moclobemide, a selective, reversible monoamine oxidase-A inhibitor, on plasma concentrations of monoamines and monoamine metabolites were determined. Moclobemide 138-149 monoamine oxidase A Homo sapiens 175-194 8880082-1 1996 The metabolic fate of moclobemide (Ro 11-1163), a new reversible and selective inhibitor of monoamine oxidase type A (MAO-A), has been assessed in a pilot study in 2 debrisoquine poor metabolizers (PM) and 4 extensive metabolizers (EM) after multiple oral dosings of moclobemide with and without co-medication of dextromethorphan. Moclobemide 22-33 monoamine oxidase A Homo sapiens 92-116 8880082-1 1996 The metabolic fate of moclobemide (Ro 11-1163), a new reversible and selective inhibitor of monoamine oxidase type A (MAO-A), has been assessed in a pilot study in 2 debrisoquine poor metabolizers (PM) and 4 extensive metabolizers (EM) after multiple oral dosings of moclobemide with and without co-medication of dextromethorphan. Moclobemide 22-33 monoamine oxidase A Homo sapiens 118-123 8880082-1 1996 The metabolic fate of moclobemide (Ro 11-1163), a new reversible and selective inhibitor of monoamine oxidase type A (MAO-A), has been assessed in a pilot study in 2 debrisoquine poor metabolizers (PM) and 4 extensive metabolizers (EM) after multiple oral dosings of moclobemide with and without co-medication of dextromethorphan. Moclobemide 35-45 monoamine oxidase A Homo sapiens 92-116 8880082-1 1996 The metabolic fate of moclobemide (Ro 11-1163), a new reversible and selective inhibitor of monoamine oxidase type A (MAO-A), has been assessed in a pilot study in 2 debrisoquine poor metabolizers (PM) and 4 extensive metabolizers (EM) after multiple oral dosings of moclobemide with and without co-medication of dextromethorphan. Moclobemide 35-45 monoamine oxidase A Homo sapiens 118-123 8848950-2 1995 The efficacy and the safety of moclobemide (400-600 mg/day), a reversible and selective inhibitor of monoamine oxidase-A (RIMA) and of clomipramine (100-150 mg/day) were compared respectively in 98 and 93 nonmelancholic, nonpsychotic out-patients with a DSM-III major depressive episode over 6 weeks and up to 3 months, in a multi-center double-blind trial. Moclobemide 31-42 monoamine oxidase A Homo sapiens 101-120 7572258-1 1995 A total of 56 patients attending a general practitioner for treatment of depression, most of whom met the criteria for major depression, were included in this double-blind, parallel group, 6-week study, in which the selective MAO-A inhibitor moclobemide (MOC; maximum dose 600 mg) was compared with the tricyclic antidepressant doxepin (DOX; maximum dose 250 mg). Moclobemide 242-253 monoamine oxidase A Homo sapiens 226-231 7593732-0 1995 The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson"s disease. Moclobemide 29-40 monoamine oxidase A Homo sapiens 65-84 7714227-2 1995 A switch in treatment from TCAs to moclobemide, a reversible and selective inhibitor of MAO-A, was investigated in a double-blind, placebo-controlled study in healthy volunteers. Moclobemide 35-46 monoamine oxidase A Homo sapiens 88-93 7781267-1 1995 The reversible monoamine oxidase A inhibitor moclobemide was given in single (300 mg) and multiple doses (600 mg/day) to 11 male and four female healthy volunteers (age range, 23 to 27) who were either poor metabolizers of S-mephenytoin (n = 7) or extensive metabolizers of S-mephenytoin (n = 8). Moclobemide 45-56 monoamine oxidase A Homo sapiens 15-34 7772614-8 1995 Thus far only a small number of studies with selective MAO-A inhibitors, such as moclobemide and brofaromine, have been conducted in social phobia, and the results indicate that both compounds are effective. Moclobemide 81-92 monoamine oxidase A Homo sapiens 55-60 7717091-1 1995 This article reviews efficacy studies of the reversible selective inhibitor of monoamine oxidase A (MAO-A) moclobemide, which has now received extensive evaluation. Moclobemide 107-118 monoamine oxidase A Homo sapiens 79-98 7717091-1 1995 This article reviews efficacy studies of the reversible selective inhibitor of monoamine oxidase A (MAO-A) moclobemide, which has now received extensive evaluation. Moclobemide 107-118 monoamine oxidase A Homo sapiens 100-105 7519866-0 1994 Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor. Moclobemide 51-62 monoamine oxidase A Homo sapiens 0-19 8056992-2 1994 The reversible, selective monoamine oxidase A inhibitor moclobemide (450 mg daily) was compared with imipramine (150 mg daily) and placebo in a multicentre, controlled clinical trial lasting 6 weeks. Moclobemide 56-67 monoamine oxidase A Homo sapiens 26-45 7952273-10 1994 Correspondingly, 2 h after the oral administration of supramaximal doses of the MAO-A inhibitors moclobemide and Ro 41-1049 (but not the MAO-B inhibitor lazabemide) the in vitro binding of [3H]SR 95531 was markedly reduced (by 77 and 82% of controls respectively). Moclobemide 97-108 monoamine oxidase A Homo sapiens 80-85 7519866-2 1994 Single oral doses of 300, 450 and 600 mg moclobemide, a monoamine oxidase type A inhibitor, were administered in a cross-over design to eight healthy male volunteers. Moclobemide 41-52 monoamine oxidase A Homo sapiens 56-80 8127928-1 1993 Moclobemide is the first of a new generation of reversible inhibitors of monoamine oxidase-A (RIMA) with no clinically relevant potentiation of the hypertensive actions of dietary tyramine. Moclobemide 0-11 monoamine oxidase A Homo sapiens 73-92 7800155-0 1994 Effects of long-term treatment with the MAO-A inhibitor moclobemide on sleep EEG and nocturnal hormonal secretion in normal men. Moclobemide 56-67 monoamine oxidase A Homo sapiens 40-45 7800155-1 1994 Sleep EEG, nocturnal penile tumescence (NPT) and nocturnal hormone secretion were studied in four normal males during placebo, under up to 300 mg per day of moclobemide, the short-acting and reversible inhibitor of monoamine oxidase (type A), and after withdrawal. Moclobemide 157-168 monoamine oxidase A Homo sapiens 215-240 8208985-2 1994 Moclobemide (Aurorix) is a newly developed, effective, short-acting well tolerable and safe antidepressant which belongs to the new class of reversible monoamine-oxidase-A inhibitors. Moclobemide 0-11 monoamine oxidase A Homo sapiens 152-171 8208985-2 1994 Moclobemide (Aurorix) is a newly developed, effective, short-acting well tolerable and safe antidepressant which belongs to the new class of reversible monoamine-oxidase-A inhibitors. Moclobemide 13-20 monoamine oxidase A Homo sapiens 152-171 7954485-1 1994 Moclobemide, a novel monoamine oxidase-A reversible inhibitor with demonstrated antidepressive efficacy, was administered double-blind versus imipramine to aged depressive subjects. Moclobemide 0-11 monoamine oxidase A Homo sapiens 21-40 8296582-2 1993 A comparison of the selective monoamine oxidase A inhibitor moclobemide and placebo. Moclobemide 60-71 monoamine oxidase A Homo sapiens 30-49 8296582-3 1993 Thirty-four patients with seasonal affective disorder, winter depression type (WD) were randomly distributed to receive the selective monoamine oxidase-A inhibitor moclobemide (400 mg daily) or placebo in a double-blind, parallel group study lasting for up to 14 weeks. Moclobemide 164-175 monoamine oxidase A Homo sapiens 134-153 7905288-0 1993 Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide. Moclobemide 81-92 monoamine oxidase A Homo sapiens 58-63 7905288-1 1993 Moclobemide, p-chloro-N-[morpholinoethyl]benzamide, is a prototype of RIMA (reversible inhibitor of MAO-A) agents. Moclobemide 0-11 monoamine oxidase A Homo sapiens 100-105 8490690-0 1993 Moclobemide: a reversible inhibitor of monoamine oxidase type A. Moclobemide 0-11 monoamine oxidase A Homo sapiens 39-63 8354766-0 1993 Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Moclobemide 0-11 monoamine oxidase A Homo sapiens 26-31 8488751-1 1993 The clinical efficacy of the monoamine oxidase A inhibitor moclobemide and its effect on the dexamethasone suppression test (DST) and plasma and urine methoxyhydroxyphenylglycol (MHPG) were investigated in 26 depressed patients during a 4-week clinical trial. Moclobemide 59-70 monoamine oxidase A Homo sapiens 29-48 8255982-2 1993 Moclobemide is a novel benzamide reversible inhibitor of monoamine oxidase A and has clinical efficacy in a wide spectrum of depressive illness including endogenous and non-endogenous depression, in younger adults and in the elderly. Moclobemide 0-11 monoamine oxidase A Homo sapiens 57-76 8490690-2 1993 Moclobemide, the first reversible inhibitor of monoamine oxidase type A to enter widespread clinical use, has a number of advantages over traditional monoamine oxidase inhibitors and represents a valuable addition to the antidepressant armamentarium. Moclobemide 0-11 monoamine oxidase A Homo sapiens 47-71 8468439-2 1993 However, moclobemide, a selective reversible inhibitor of MAO-A, has a low propensity for producing drug interactions. Moclobemide 9-20 monoamine oxidase A Homo sapiens 58-63 8313399-3 1993 Moclobemide is the first reversible MAO-A inhibitor to be widely marketed and is currently approved for marketing in approximately 50 countries. Moclobemide 0-11 monoamine oxidase A Homo sapiens 36-41 8313400-5 1993 More studies on the benefits of the new MAO-A inhibitors in resistant depression are indicated, not only with brofaromine but also with moclobemide, which to date has not been studied in this indication. Moclobemide 136-147 monoamine oxidase A Homo sapiens 40-45 8313401-2 1993 The new, selective, and reversible MAO-A inhibitors exemplified by brofaromine and moclobemide do not require dietary restrictions, have fewer drug interactions, and are better tolerated. Moclobemide 83-94 monoamine oxidase A Homo sapiens 35-40 1393304-2 1992 In a double-blind, parallel group trial, 78 subjects with social phobia received moclobemide (a new reversible inhibitor of monoamine oxidase A) phenelzine, or placebo. Moclobemide 81-92 monoamine oxidase A Homo sapiens 124-143 1417632-2 1992 Moclobemide is a specific monoamine oxidase-A inhibitor which does not bind irreversibly to the enzyme, unlike the currently available MAOIs. Moclobemide 0-11 monoamine oxidase A Homo sapiens 26-45 1394030-2 1992 Moclobemide represents a new class of drug, the so-called RIMA compounds--reversible inhibitors of MAO-A. Moclobemide 0-11 monoamine oxidase A Homo sapiens 99-104 1580888-7 1992 Moclobemide, a specific, reversible inhibitor of MAO-A, has been extensively evaluated in depressive illness. Moclobemide 0-11 monoamine oxidase A Homo sapiens 49-54 1546127-1 1992 Moclobemide is a reversible inhibitor of the monoamine oxidase type A. Moclobemide 0-11 monoamine oxidase A Homo sapiens 45-69 1418864-0 1992 Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity. Moclobemide 69-80 monoamine oxidase A Homo sapiens 24-29 1347658-3 1992 A new class of RIMA (Reversible Inhibitors of MAO-A) represented by moclobemide requires a change in clinical thinking on antidepressants. Moclobemide 68-79 monoamine oxidase A Homo sapiens 46-51 1347659-5 1992 The inhibitory activity of moclobemide on MAO-A was reflected in significant reductions of plasma concentrations of DHPG and 5-HIAA. Moclobemide 27-38 monoamine oxidase A Homo sapiens 42-47 1347659-9 1992 Thus, single oral doses of 300, 450 and 600 mg moclobemide demonstrated marked inhibition of MAO-A activity, whereas a single dose of 300 mg induced a near-maximum effect. Moclobemide 47-58 monoamine oxidase A Homo sapiens 93-98 1483487-1 1992 An open study was carried out to examine the effect of moclobemide, a new antidepressant reversible inhibitor of MAO-A, on the pressor response induced by oral tyramine added to meals of different lipid and protein composition, and to correlate the blood pressure increase in the tyramine test with that obtained during an exercise test. Moclobemide 55-66 monoamine oxidase A Homo sapiens 113-118 1546129-3 1992 To test this, moclobemide, a new and reversible inhibitor of monoamine oxidase-A, was administered to 12 children between the ages of 6 and 13 years, diagnosed as attention deficit hyperactive according to DSM III-R, in a 4-week study. Moclobemide 14-25 monoamine oxidase A Homo sapiens 61-80 1546132-0 1992 Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide. Moclobemide 72-83 monoamine oxidase A Homo sapiens 38-57 1546132-1 1992 The mode of interaction of the reversible monoamine oxidase-A (MAO-A) inhibitor moclobemide with the enzyme was investigated. Moclobemide 80-91 monoamine oxidase A Homo sapiens 42-61 1546132-1 1992 The mode of interaction of the reversible monoamine oxidase-A (MAO-A) inhibitor moclobemide with the enzyme was investigated. Moclobemide 80-91 monoamine oxidase A Homo sapiens 63-68 1546132-2 1992 The inhibition of rat brain or human placenta MAO-A by moclobemide showed an initial competitive phase, with a relatively low affinity (KI = 0.2-0.4 mM). Moclobemide 55-66 monoamine oxidase A Homo sapiens 46-51 1546132-4 1992 The time-dependent component of the association of moclobemide with MAO-A followed pseudo-first order kinetics. Moclobemide 51-62 monoamine oxidase A Homo sapiens 68-73 1546132-6 1992 Even though some aspects of the moclobemide interaction with MAO-A are still not completely elucidated, this compound seems to have the characteristics of a slow-binding inhibitor. Moclobemide 32-43 monoamine oxidase A Homo sapiens 61-66 1546142-7 1992 It may be explained by moclobemide"s selective and reversible inhibition of monoamine oxidase A, as well as by the lack of any anticholinergic action. Moclobemide 23-34 monoamine oxidase A Homo sapiens 76-95 1546143-1 1992 RIMA is a term for reversible inhibitors of monoamine oxidase (MAO) with preference for MAO-A; moclobemide is a prototype of this new class of antidepressants and is a highly selective inhibitor of MAO-A in vitro. Moclobemide 95-106 monoamine oxidase A Homo sapiens 88-93 1546143-1 1992 RIMA is a term for reversible inhibitors of monoamine oxidase (MAO) with preference for MAO-A; moclobemide is a prototype of this new class of antidepressants and is a highly selective inhibitor of MAO-A in vitro. Moclobemide 95-106 monoamine oxidase A Homo sapiens 198-203 1546152-4 1992 The design of controlled clinical trials to compare the effects of moclobemide, a new and selective monoamine oxidase-A inhibitor, with those of standard tricyclic antidepressant drugs involved the refinement of selection strategies, formulation of hypotheses, means of statistical analysis and clinical interpretation. Moclobemide 67-78 monoamine oxidase A Homo sapiens 100-119 1812674-0 1991 [Effectiveness and tolerance of the selective MAO-A inhibitor moclobemide in children with hyperkinetic syndrome]. Moclobemide 62-73 monoamine oxidase A Homo sapiens 46-51 1812674-4 1991 In an open clinical study we administered moclobemide, a new reversible MAO-A inhibitor, to children who fulfilled the diagnostic criteria for hyperkinetic syndrome according to ICD-9 (314). Moclobemide 42-53 monoamine oxidase A Homo sapiens 72-77 1988238-0 1991 Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. Moclobemide 80-91 monoamine oxidase A Homo sapiens 50-69 1687486-0 1991 Successful treatment of tardive akathisia with moclobemide, a reversible and selective monoamine-oxidase-A inhibitor. Moclobemide 47-58 monoamine oxidase A Homo sapiens 87-106 1687486-4 1991 In this case report, TA that occurred in the course of a tardive dyskinesia (TD) was successfully treated with the monoamine-oxidase-A inhibitor moclobemide. Moclobemide 145-156 monoamine oxidase A Homo sapiens 115-134 1904620-2 1991 Moclobemide belongs to a new class of substances called RIMA (Reversible Inhibitor of the monoamine oxidase type A). Moclobemide 0-11 monoamine oxidase A Homo sapiens 90-114 2250565-0 1990 Evidence that the reversible MAO-A inhibitor moclobemide increases prolactin secretion by a serotonergic mechanism in healthy male volunteers. Moclobemide 45-56 monoamine oxidase A Homo sapiens 29-34 2123366-0 1990 Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Moclobemide 16-27 monoamine oxidase A Homo sapiens 59-78 2123366-1 1990 Moclobemide, a new selective and reversible inhibitor of monoamine oxidase A (RIMA), has been compared with various tricyclic antidepressants (TCAs) in numerous controlled studies. Moclobemide 0-11 monoamine oxidase A Homo sapiens 57-76 2089088-0 1990 Psychometric alterations in treatment with the MAO-A-inhibitor moclobemide. Moclobemide 63-74 monoamine oxidase A Homo sapiens 47-52 2089089-0 1990 Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder. Moclobemide 78-89 monoamine oxidase A Homo sapiens 61-66 2089089-1 1990 N = 53 inpatients with major depressive disorder have been treated with the reversible, selective MAO-A-inhibitors moclobemide (double-blind versus maprotiline) and brofaromine (open study), respectively. Moclobemide 115-126 monoamine oxidase A Homo sapiens 98-103 2250565-1 1990 The serotonin receptor antagonist methysergide was used to investigate the mechanism mediating stimulation of prolactin release after single doses of the reversible MAO-A inhibitor moclobemide. Moclobemide 181-192 monoamine oxidase A Homo sapiens 165-170 1646924-4 1991 In contrast, a single dose of the reversible monoamine oxidase type A (MAO-A) inhibitor moclobemide reduced plasma DHPG levels by 78% and MHPG levels by 51%. Moclobemide 88-99 monoamine oxidase A Homo sapiens 45-69 1646924-4 1991 In contrast, a single dose of the reversible monoamine oxidase type A (MAO-A) inhibitor moclobemide reduced plasma DHPG levels by 78% and MHPG levels by 51%. Moclobemide 88-99 monoamine oxidase A Homo sapiens 71-76 1705137-12 1990 Before the next drug intake, MAO-A inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with moclobemide but not with toloxatone. Moclobemide 149-160 monoamine oxidase A Homo sapiens 29-34 2248061-6 1990 Since the concentration of Ro 16-6491 in human plasma remains below the limit of detection, only a very weak inhibition of MAO-B is produced in human platelets, and moclobemide can thus be considered a selective MAO-A inhibitor in humans. Moclobemide 165-176 monoamine oxidase A Homo sapiens 212-217 2248062-1 1990 The acute psychomotor effects of moclobemide, a reversible inhibitor of MAO-A antidepressant (100 and 300 mg) compared with amitriptyline (25 and 75 mg) showed that moclobemide caused no significant impairment in contrast with amitriptyline, which caused significant impairment at both doses. Moclobemide 33-44 monoamine oxidase A Homo sapiens 72-77 2248063-2 1990 Moclobemide, a reversible inhibitor of monoamine oxidase (RIMA), preferentially inhibits MAO-A. Moclobemide 0-11 monoamine oxidase A Homo sapiens 89-94 2248082-9 1990 The authors conclude that, because of the short-lasting, reversible and selective MAO-A-inhibiting effect of moclobemide, there is no marked interaction with tyramine given by i.v. Moclobemide 109-120 monoamine oxidase A Homo sapiens 82-87 2248084-1 1990 The pharmacodynamic properties of moclobemide, a reversible inhibitor of MAO-A (RIMA), were compared with the properties of other reversible as well as older irreversible MAO inhibitors in human subjects. Moclobemide 34-45 monoamine oxidase A Homo sapiens 73-78 2248084-5 1990 Moclobemide and clorgyline were found to be the most highly selective MAO-A inhibitors, although both also inhibited 30% of platelet MAO-B activity. Moclobemide 0-11 monoamine oxidase A Homo sapiens 70-75 1965198-1 1990 The effect of chronic treatment with the selective and reversible MAO-A-inhibitor moclobemide (MOC) vs. the norepinephrine reuptake inhibitor maprotiline (MAP) on alpha 2-adrenoceptor responsivity was studied by clonidine (CLON)-evoked growth hormone (GH) release in major depressive disorder. Moclobemide 82-93 monoamine oxidase A Homo sapiens 66-71 2193111-0 1990 From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. Moclobemide 5-16 monoamine oxidase A Homo sapiens 103-108 2193111-1 1990 This study describes the serendipitous discovery of moclobemide, a short-acting MAO-A inhibitor which is in an advanced stage of clinical development as an antidepressant. Moclobemide 52-63 monoamine oxidase A Homo sapiens 80-85 2300680-0 1990 Moclobemide, an inhibitor of MAO-A, does not increase daytime plasma melatonin levels in normal humans. Moclobemide 0-11 monoamine oxidase A Homo sapiens 29-34 2312783-0 1990 Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function. Moclobemide 24-35 monoamine oxidase A Homo sapiens 43-48 2619973-2 1989 Administration of moclobemide--a relatively short-acting, reversible inhibitor of monoamine oxidase-A (MAO-A)--to experimental animals potentiates the pressor responses to intravenously injected tyramine, but such effects are moderate, short-lived, and much less apparent when the tyramine is given orally. Moclobemide 18-29 monoamine oxidase A Homo sapiens 82-101 34102520-4 2021 Compounds 2a, 2k, 4a and 4i showed significant inhibitory activity against MAO-A, with IC50 value in the range of 0.084-0.207 microM compared to reference drug moclobemide (IC50 value = 6.061 microM). Moclobemide 160-171 monoamine oxidase A Homo sapiens 75-80 2695130-1 1989 The antidepressant efficacy, tolerability, and safety of moclobemide, a reversible, monoamine oxidase-A inhibitor, were compared with those of imipramine in parallel groups of patients with a major depressive episode, in a 4-week, multicentre (17 centres), randomised study. Moclobemide 57-68 monoamine oxidase A Homo sapiens 84-103 2619973-2 1989 Administration of moclobemide--a relatively short-acting, reversible inhibitor of monoamine oxidase-A (MAO-A)--to experimental animals potentiates the pressor responses to intravenously injected tyramine, but such effects are moderate, short-lived, and much less apparent when the tyramine is given orally. Moclobemide 18-29 monoamine oxidase A Homo sapiens 103-108 2619973-3 1989 The ability of moclobemide to potentiate the pharmacological actions of amine substrates for MAO-A in in vitro preparations is very weak, unless the drug is "activated" by prior incubation with the tissues. Moclobemide 15-26 monoamine oxidase A Homo sapiens 93-98 2619974-0 1989 Effect of a reversible monoamine oxidase-A inhibitor (moclobemide) on sleep of depressed patients. Moclobemide 54-65 monoamine oxidase A Homo sapiens 23-42 2619974-1 1989 The effect of moclobemide, a short-acting, reversible, preferential monoamine oxidase-A inhibitor in a 4-week therapeutic trial, on the sleep of ten depressed patients, was assessed by polysomnographic recordings. Moclobemide 14-25 monoamine oxidase A Homo sapiens 68-87 2587674-9 1989 The results suggest that the two reversible MAO-A inhibitors moclobemide and brofaromine carry a much reduced liability to tyramine-related hypertensive reactions. Moclobemide 61-72 monoamine oxidase A Homo sapiens 44-49 2511580-1 1989 13 patients with major depressive disorder, who responded well to the reversible MAO-A-inhibitor moclobemide after unsuccessful initial treatment with tri- or tetracyclic antidepressants were monitored under naturalistic outpatient therapy conditions with moclobemide plasma level control for an average of 7.4 months. Moclobemide 97-108 monoamine oxidase A Homo sapiens 81-86 2685852-3 1989 The objective of the present review is to evaluate the pharmacokinetics of five MAO-A inhibitors (moclobemide, toloxatone, brofaromine, cimoxatone, amiflamine). Moclobemide 98-109 monoamine oxidase A Homo sapiens 80-85 2685855-1 1989 Moclobemide, a benzamidederivate, is a reversible, selective MAOI with a predominant effect upon MAO-A. Moclobemide 0-11 monoamine oxidase A Homo sapiens 97-102 2685856-0 1989 [Treatment of depression using MAO-A inhibitors: an open study of a direct switch from moclobemide to tri-/tetracyclic antidepressants]. Moclobemide 87-98 monoamine oxidase A Homo sapiens 31-36 2685856-1 1989 In an open study 13 depressed inpatients received moclobemide, a selective and reversible MAO-A-inhibitor (300 mg/d) for one week and subsequently were switched to a three-week course of a tricyclic or tetracyclic antidepressant (TCA) without medication-free interval. Moclobemide 50-61 monoamine oxidase A Homo sapiens 90-95 2673623-2 1989 Moclobemide is a new, reversible, preferential monoamine oxidase A inhibitor with antidepressant properties. Moclobemide 0-11 monoamine oxidase A Homo sapiens 47-66 2587675-0 1989 [Psychometric findings in treatment using the selective MAO-A inhibitors moclobemide and maprotiline]. Moclobemide 73-84 monoamine oxidase A Homo sapiens 56-61 2469451-9 1989 Due to the rapid, reversible, dose-dependent and MAO-A specific effect of moclobemide on plasma concentrations of DHPG, it is suggested that DHPG in plasma may be a useful indicator of the magnitude and duration of MAO-A inhibition in man. Moclobemide 74-85 monoamine oxidase A Homo sapiens 49-54 2469451-9 1989 Due to the rapid, reversible, dose-dependent and MAO-A specific effect of moclobemide on plasma concentrations of DHPG, it is suggested that DHPG in plasma may be a useful indicator of the magnitude and duration of MAO-A inhibition in man. Moclobemide 74-85 monoamine oxidase A Homo sapiens 215-220 2714732-1 1989 We investigated the pressor response to oral tyramine before and during treatment with moclobemide, a selective monoamine oxidase-A inhibitor, in 10 depressed patients. Moclobemide 87-98 monoamine oxidase A Homo sapiens 112-131 2508163-1 1989 The concentration of the reversible monoamine oxidase type-A (MAO-A) inhibitor moclobemide (Ro 11-1163) was determined by high pressure liquid chromatography (HPLC) in the plasma of 16 depressives treated with moclobemide. Moclobemide 79-90 monoamine oxidase A Homo sapiens 36-60 22156310-0 1989 Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers. Moclobemide 123-134 monoamine oxidase A Homo sapiens 107-112 2508163-1 1989 The concentration of the reversible monoamine oxidase type-A (MAO-A) inhibitor moclobemide (Ro 11-1163) was determined by high pressure liquid chromatography (HPLC) in the plasma of 16 depressives treated with moclobemide. Moclobemide 210-221 monoamine oxidase A Homo sapiens 36-60 2508163-1 1989 The concentration of the reversible monoamine oxidase type-A (MAO-A) inhibitor moclobemide (Ro 11-1163) was determined by high pressure liquid chromatography (HPLC) in the plasma of 16 depressives treated with moclobemide. Moclobemide 79-90 monoamine oxidase A Homo sapiens 62-67 2508163-1 1989 The concentration of the reversible monoamine oxidase type-A (MAO-A) inhibitor moclobemide (Ro 11-1163) was determined by high pressure liquid chromatography (HPLC) in the plasma of 16 depressives treated with moclobemide. Moclobemide 92-102 monoamine oxidase A Homo sapiens 36-60 2508163-1 1989 The concentration of the reversible monoamine oxidase type-A (MAO-A) inhibitor moclobemide (Ro 11-1163) was determined by high pressure liquid chromatography (HPLC) in the plasma of 16 depressives treated with moclobemide. Moclobemide 92-102 monoamine oxidase A Homo sapiens 62-67 3045798-3 1988 The most selective MAO-A inhibitors are moclobemide and brofaromine, with ratios between their MAO-A and MAO-B inhibiting potency (estimated in in vitro assays) of 1: greater than or equal to 1000 and 1:500, respectively, whereas the least selective drug is cimoxatone with a ratio of 1:66. Moclobemide 40-51 monoamine oxidase A Homo sapiens 19-24 2452231-1 1988 In this paper the preliminary results from an ongoing investigation on the effect of the MAO-A inhibitor moclobemide on clinicolaboratory variables (antidepressant effect, platelet MAO activity, urinary MHPG and 5-HIAA excretion, plasma prolactin and growth hormone levels and TSH response to TRH) are reported. Moclobemide 105-116 monoamine oxidase A Homo sapiens 89-94 3045798-5 1988 After oral administration, however, cimoxatone, brofaromine and moclobemide appear to be about equally effective in inhibiting brain MAO-A. Moclobemide 64-75 monoamine oxidase A Homo sapiens 133-138 3045798-3 1988 The most selective MAO-A inhibitors are moclobemide and brofaromine, with ratios between their MAO-A and MAO-B inhibiting potency (estimated in in vitro assays) of 1: greater than or equal to 1000 and 1:500, respectively, whereas the least selective drug is cimoxatone with a ratio of 1:66. Moclobemide 40-51 monoamine oxidase A Homo sapiens 95-100 6429130-5 1984 An alternative approach in the development of safer, effective MAOIs is the use of rapidly reversible MAO-A inhibitors, such as moclobemide, that carry less risk of a hypertensive reaction and yet appear to be effective antidepressants. Moclobemide 128-139 monoamine oxidase A Homo sapiens 102-107 3665338-0 1987 Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. Moclobemide 24-35 monoamine oxidase A Homo sapiens 39-58 3298420-0 1987 A clinical study of the selective MAO-A-inhibitor moclobemide (Ro 11-1163): a comparison of 2 different dosages with particular reference to platelet MAO-activity and urinary MHPG-excretion. Moclobemide 50-61 monoamine oxidase A Homo sapiens 34-39 3298420-0 1987 A clinical study of the selective MAO-A-inhibitor moclobemide (Ro 11-1163): a comparison of 2 different dosages with particular reference to platelet MAO-activity and urinary MHPG-excretion. Moclobemide 63-73 monoamine oxidase A Homo sapiens 34-39 6388247-2 1984 Moclobemide (Ro 11-1163), a benzamide derivative, is a MAO-inhibitor which selectively and reversibly inhibits monoamine oxidase type A. Moclobemide 0-11 monoamine oxidase A Homo sapiens 111-135 6388247-2 1984 Moclobemide (Ro 11-1163), a benzamide derivative, is a MAO-inhibitor which selectively and reversibly inhibits monoamine oxidase type A. Moclobemide 13-23 monoamine oxidase A Homo sapiens 111-135 3432450-1 1987 Moclobemide is a reversible, short-acting monoamine oxidase inhibitor (MAO1), specific for MAO A. Moclobemide 0-11 monoamine oxidase A Homo sapiens 91-96 6382361-0 1984 A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor. Moclobemide 61-72 monoamine oxidase A Homo sapiens 80-85 6382361-1 1984 Preliminary open trials performed by the authors and others with Moclobemide, a new MAO-A inhibitor, indicated that the drug has a satisfactory antidepressant activity. Moclobemide 65-76 monoamine oxidase A Homo sapiens 84-89 32621059-2 2020 Here, we sought to assess the effect of the selective reversible MAO-A inhibitor moclobemide on L-DOPA anti-parkinsonian in the gold standard animal model of PD, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate. Moclobemide 81-92 monoamine oxidase A Homo sapiens 65-70 6865966-0 1983 Neurochemical effects in vitro and in vivo of the antidepressant Ro 11-1163, a specific and short-acting MAO-A inhibitor. Moclobemide 65-75 monoamine oxidase A Homo sapiens 105-110 32601846-6 2020 MAO-A inhibition with moclobemide may provide anti-parkinsonian benefit when administered without L-DOPA and might perhaps be considered as monotherapy for the treatment of Parkinson"s disease in the early stages of the condition. Moclobemide 22-33 monoamine oxidase A Homo sapiens 0-5 33085988-2 2021 The result indicated that 7,8-dihydroxy-3-(4-nitrophenyl)coumarin (3j) was most effective against MAO-A (inhibition concentration [IC50 ] = 6.46 +- 0.02 microM) and MAO-B (IC50 = 3.8 +- 0.3 microM) enzymes than other synthesized compounds and reference compounds (pargyline and moclobemide). Moclobemide 279-290 monoamine oxidase A Homo sapiens 98-103 32621059-8 2020 Reversible MAO-A inhibition with moclobemide appears as an effective way to increase the anti-parkinsonian action of L-DOPA, without negatively affecting dyskinesia or dopaminergic psychosis. Moclobemide 33-44 monoamine oxidase A Homo sapiens 11-16 30242487-2 2018 The monoamine oxidases A and B (MAOA/MAOB) are prime candidates for the investigation into the role of DNA methylation in mental disorders, given their pivotal role in the metabolism of monoamines and as pharmacological targets of potent antidepressant drugs such as tranylcypromine, phenelzine or moclobemide. Moclobemide 298-309 monoamine oxidase A Homo sapiens 32-36 32337091-5 2020 The broader substrate specificity of McbA was exploited in the synthesis of the monoamine oxidase A inhibitor moclobemide, through the reaction of 4-chlorobenzoic acid with 1.5 equiv of 4-(2-aminoethyl)morpholine, and utilizing polyphosphate kinases SmPPK and AjPPK in the presence of polyphosphoric acid and 0.1 equiv of ATP, required for recycling of the cofactor. Moclobemide 110-121 monoamine oxidase A Homo sapiens 80-99 29320717-1 2018 The imitation of phase I metabolism of moclobemide and toloxatone, two monoamine oxidase type A (MAO-A) inhibitors, was performed with the use of titanium dioxide photocatalytic process. Moclobemide 39-50 monoamine oxidase A Homo sapiens 71-95 29320717-1 2018 The imitation of phase I metabolism of moclobemide and toloxatone, two monoamine oxidase type A (MAO-A) inhibitors, was performed with the use of titanium dioxide photocatalytic process. Moclobemide 39-50 monoamine oxidase A Homo sapiens 97-102